Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CCFM1026 + GL-104 + MP108
- Development stage
- Unknown
- Lead developer
- Jiangnan University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
CCFM1026 + GL-104 + MP108 is a specific probiotic combination formulation developed for the management of hyperuricemia and gout. The formulation consists of three distinct bacterial strains: *Lactiplantibacillus plantarum* CCFM1026, *Lactobacillus reuteri* GL-104, and *Bifidobacterium animalis* subsp. *lactis* MP108. The primary functional component, CCFM1026, was screened by researchers at Jiangnan University for its significant xanthine oxidase inhibitory activity and its ability to degrade intestinal purine nucleosides such as inosine and guanosine. By reducing the availability of purine precursors and inhibiting the enzyme responsible for uric acid production in the gut, the combination aims to lower serum uric acid levels. The additional strains, GL-104 and MP108, contribute to the modulation of the gut microbiota, enhancement of intestinal barrier function, and reduction of systemic inflammation, which are critical factors in preventing gout flares. This combination is primarily marketed in China as a functional food or dietary supplement and has been the subject of clinical trials investigating its efficacy in patients with high uric acid levels.
- Brand names
- WonderLab Uric Acid Probiotic
- Other names
- Lactiplantibacillus plantarum CCFM1026 + Lactobacillus reuteri GL-104 + Bifidobacterium animalis subsp. lactis MP108Jiangnan University Uric Acid Probiotic Formula
02
Targets
XO (Xanthine Oxidoreductase)
Beyond the preview
Go deeper on CCFM1026 + GL-104 + MP108.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CCFM1026 + GL-104 + MP108.